GlassScriptPhysician profile
Zhangning Chen
NPI 1235660564
$7,826.68
in general payments reported to CMS, 2019-2025
39 companies · $7,021 in 2025
The $7,021 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $184 · 2024: $622 · 2025: $7,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,340 · Food and Beverage: $3,189 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,340.00 |
| Food and Beverage | $3,189.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $297.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,518.02 | 2024-2025 | |
| Janssen Biotech, INC. | $1,168.20 | 2024-2025 | Darzalex, Rybrevant, Tecvayli |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Caris Mpi, INC. | $278.28 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $239.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $199.99 | 2025 | |
| Astellas Pharma US INC | $198.90 | 2023-2025 | Cresemba, Padcev, Vyloy |
| Astrazeneca Pharmaceuticals LP | $195.93 | 2024-2025 | Imfinzi, Lynparza, Enhertu |
| Incyte Corporation | $173.51 | 2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $167.95 | 2025 | Enhertu, Datroway |
| Abbvie INC. | $153.86 | 2024-2025 | |
| Exelixis INC. | $152.55 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $148.88 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Geron Corporation | $122.98 | 2025 | Rytelo |
| Genzyme Corporation | $98.76 | 2024-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhangning Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.